Inclusion Criteria:~* 55-79 years old;~* ≥ 8 years of education;~* Study partner is available who has frequent
contact with the participant (e.g. an average of 10 hours per week or more), and can accompany the participant
to all clinic visits for the duration of the protocol;~* Evidence of early AD, as defined by all of the
following:~ 1. Memory complaint by subject or study partner that is verified by a study partner;~ 2. Objective
memory impairment for age, documented by scoring below the education adjusted cutoff of the Logical Memory II
subscale (Delayed Paragraph Recall) from the Wechsler Memory Scale Third Edition (the maximum score is 25):~ *
≤ 8 for 16 or more years of education, or~ * ≤ 4 for 8-15 years of education;~ * Essentially preserved general
cognitive function;~ * Largely intact functional activities;~ * Not demented;~* Cerebrospinal fluid (CSF)
biomarker results consistent with early AD, including CSF AÎ²-42 levels ≥ 180 pg/mL and ≤ 690 pg/mL;~* Clinical
Dementia Rating (Global) = 0.5; Memory Box score must be at least 0.5;~* Must be fluent in the language of the
cognitive testing material being administered;~* Stability of permitted medications for 4 weeks prior to study
start; subjects receiving acetylcholinesterase inhibitors and/or memantine should be on stable dose of those
medications for at least 12 weeks prior to study start with every effort to maintain stable dose for the
duration of the study;~* Visual and auditory acuity adequate for neuropsychological testing;~* Good general
health with no diseases expected to interfere with the study;~* Must provide written informed consent for APOe4
genotype testing;~* Must provide written informed consent for CSF sampling.~
